Geneva, Switzerland - 24 March 2017 - ObsEva SA (Nasdaq: OBSV), a Swiss biopharmaceutical company focused
on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health
and pregnancy, today announced that Ernest LOUMAYE, M.D., Ph.D., CEO and Co-Founder and Tim ADAMS, CFO, will attend the
16th Annual Needham Healthcare Conference. Management will be presenting on Tuesday April 4 at 3:40 pm and will be
hosting one-on-one meetings on April 4 and 5, 2017 at the Westin New York Grand Central Hotel.
About ObsEva
ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization
of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. Through strategic
in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs
focused on treating endometriosis, uterine fibroids, preterm labor and improving ART outcomes. ObsEva is listed on The NASDAQ
Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.
###
Media Contact:
Liz Bryan
Spectrum Science
lbryan@spectrumscience.com
202-955-6222 x2526
Company Contact:
Delphine Renaud
ObsEva, CEO Office
delphine.renaud@obseva.ch
+41 22 552 1550
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/571924da-1372-41eb-98ea-95ecb31fd84b
